source
- Encoded Therapeutics raises $275 million in Series F round for Dravet syndrome programEncoded Therapeutics announced closing a Series F financing round that brought in $275 million. The round was led by GV with participation from an undisclosed healthcare investor. The new capital…
- Gilead says its oncology and inflammation portfolio has reached critical mass after series of acquisitionsGilead Sciences CEO Daniel O’Day told Fierce that the company’s push into oncology and inflammation has now reached a point of critical mass, with a pipeline that spans early research to late‑stage…